Table 1.
Patient characteristics at start of study
| Characteristic | Group A | Group B |
|---|---|---|
| Patients (n) | 30 | 30 |
| Age (yr) | 10±3.3 | 9.5±4.0 |
| Height (cm) | 138.0±17.0 | 137.7±21.5 |
| eGFR (Schwartz) | 114.7±24.5 | 119.03±28.3 |
| Previous medicationsa | ||
| None | 8 | 6 |
| Levamisole | 5 | 3 |
| Cyclophosphamide | 13 | 22 |
| Chlorambucil | 1 | 1 |
| CsA | 14 | 12 |
| MMF | 2 | 1 |
| Duration of disease before study entry (yr) | 5.61±4.17 (0.4–14.6); median 4.7 | 5.52±4.09 (0.5–15.9); median 4.1 |
| Relapses before study entry (n) | 9.3±6.71 | 10.0±5.59 |
| Patients with steroid-dependent nephrotic syndrome (n) | 23 | 23 |
a
Some patients had received more than one previous course of immunosuppressive therapy before study (Supplemental Table 1).